PDF Cohorts
01 / 17

TriStar Technology Group

Quality biospecimens,
imaging & data for
precision medicine

FFPE surgical samples — Primary tumors, Mets, Normal (non-malignant) tissues

Donors from UK, Italy, France with informed consent & ethics approval

Clinical follow-up data including treatment, response, OS & PFS

Responders & non-responders to SOC treatment including CKI/IO

Mutations, fusions and other diagnostic markers

Expert IHC capabilities — over 100 optimized assays

02 / 17

Imaging + Clinical Data.

Whole-slide imaging tied back to the matched surgical section and the clinical timeline behind every donor. Radiology coming soon.

Radiology Coming soon Radiological images — capability in development.

Pathology

Whole-slide imaging (WSI)

Current H&E repository

30,000

donors

>100,000

H&E images

  • Aperio GT450 & AT2 scanners — same platforms used in clinical practice
  • 40× standard scan resolution across the repository
  • .svs files compatible with all major WSI viewers and AI pipelines
  • Scanned in-house — no vendor coordination, no provenance gaps
  • Pathologist-reviewed — every H&E and corresponding image checked by an experienced medical pathologist to confirm image quality is suitable for AI

Linkage

Every imaging asset is linked to

Imaging Whole-slide imaging
Surgical section Matched FFPE block & slides
Clinical data Treatment, response, OS/PFS, molecular
03 / 17

Breadth of donor profiles.

Specimen, treatment, outcomes, and molecular data — structured at the patient level.

Patient trajectory

Primary & matched distant mets Matched normal tissue Neoadjuvant › adjuvant › SOC targeted & CKI/IO

Outcomes, structured

Overall Survival (months) Progression-Free Survival (months) Time to events (TTE months) Last follow-up Event flags (recurrence / death / composite)

Molecular characterization

IHC FISH RNA-ISH NGS: SNV, CNV, Fusions

Records are fully anonymized. Not every patient has every field populated, and not every project needs every field. Cohorts are pulled to fit the project; populated fields reflect real-world clinical practice at the source center.

See an example record
04 / 17

Cohorts available.

Tumor types by cohort designs we maintain.

Jump to cohort detail
Tumor type Advanced (III/IV) Longitudinal Primary + matched mets Pre / Post SOC Pre / Post IO
NSCLC ✓ ✓ ✓ ✓ ✓
CRC ✓ ✓ ✓ ✓ —
Ovarian ✓ ✓ ✓ ✓ —
Breast ✓ ✓ ✓ ✓ —
Gastric ✓ ✓ ✓ ✓ —
Head & Neck SCC ✓ ✓ ✓ ✓ ✓
Prostate (mCRPC) ✓ ✓ — ✓ —
Endometrial ✓ ✓ ✓ ✓ —
Pancreatic ADC ✓ — — ✓ —
Bladder (UC) ✓ ✓ ✓ ✓ —
Melanoma ✓ ✓ ✓ ✓ ✓
RCC ✓ ✓ ✓ ✓ ✓
HCC ✓ ✓ ✓ ✓ —
Esophageal ✓ ✓ ✓ ✓ —

All cohorts are available as FFPE, TMA, or slides. Treatment, response, OS/PFS data and indication-specific molecular characterization (IHC and mutation panels) are linked at the patient level.

05 / 17

Uniquely positioned to support Oncology AI companies today.

Quality, standardized datasets with matching samples to support their algorithmic products and pharma services.

Ready to ship

Pre-designed cohorts

Multiple indication cohorts ready off the shelf — each comes with linked imaging, surgical samples, clinical timeline, and molecular characterization.

Built to spec

Custom cohort design

We build cohorts to your protocol — indication, stage, treatment line, biomarker, and follow-up requirements all configurable.

Expand

Complement existing cohorts

Expand on your existing cohorts with our datasets to meet the sample size needed for projects.

Profile

Expand tumor profiling

Expand clinical molecular data by sequencing the matched samples with a larger panel or for new relevant biomarkers.

Validate

Validation cohorts

Confirm your algorithmic product programs with a cohort that validates results against the biological sample utilizing our linked samples.

06 / 17

A repository purpose-built for translational medicine in oncology.

Standardized, sample-linked, anonymized patient, clinical, and molecular data — in-depth where translational science needs depth.

  • Anonymized and sample-linked — anonymized before it enters our collection and linked to physical specimen(s) in our repository.
  • Standardized data scope reflects what translational programs actually need to make decisions.
  • Specimens behind the records — the underlying tissue is available for re-staining, re-extraction, or re-characterization.
  • IHC, NGS, RNA-Seq, RNAScope, DSP, and digital image analysis — orthogonal testing in a single lab.
  • Expand the molecular profile — additional panel sequencing on the same blocks as markers of interest emerge.
  • Same patients, new questions — the data set extends with the program, without re-sourcing.
07 / 17

A core partner for translational programs.

Why top pharma and biotechs working on oncology therapeutics work with us.

  • The translational bar has moved. Sponsors developing oncology therapeutics need high-quality samples paired with in-depth, standardized data across EHR and orthogonal sources.
  • Ethically sourced, quality samples and data. Quality samples and data improve the reliability of results.
  • Validation for regulators. Data derived from TriStar samples is frequently included in IND submissions — tissue quality and annotation rigor shape what is defensible.
  • Validation for the program. Translational evidence is increasingly what investment committees and partnership negotiations anchor on.
  • Translational evidence is increasingly the rate-limiting step. Tissue quality, annotation depth, and provenance decide whether downstream analysis withstands scientific and regulatory scrutiny.
08 / 17

Scanning capabilities.

How cohorts arrive in your environment.

Magnification

40×

Standard scan resolution across the repository.

Scanners

Aperio GT450 & AT2

Whole-slide imaging on the same platforms used in clinical practice.

File format

.svs

Whole-slide files compatible with all major WSI viewers and AI pipelines.

Cloud handoff

Your choice*

*Box, AWS, Azure etc. or your company's approved procurement / data portal.

09 / 17

Lab capabilities — validation, extension & characterization.

Run in-house on the same donors and samples behind every cohort — no vendor coordination, no provenance gaps.

100+ Optimized IHC assays
Developed for
  • Ventana Benchmark
  • Dako autostainers
3 Medical pathologists 15+ combined years in pharma
Services
  • IHC
  • RNAScope
  • NGS
  • RNA-Seq
  • Digital Spatial Profiling
  • Digital image analysis
10 / 17

Advanced disease (Stage III/IV) surgical samples

Approximate number of donors

500–900 per tumor type

Tumor types

NSCLC CRC Ovarian Prostate (mCRPC) Breast Gastric Endometrial Pancreatic ADC Bladder (UC) Melanoma RCC HCC Esophageal Head & Neck SCC

Follow-up data

Treatment Response OS/PFS

Mutations*

KRAS NRAS EGFR ALK fusion BRAF BRCA MET alteration HRD status MSI status

* as available from donor records

IHC markers

ER/PR HER2 MMR IHC PD-L1 TROP2 Nectin-4 B7-H3 B7-H4 DLL3 p16 p53

HBS formats

FFPE TMA Slides
Example HBS Cohorts & Data Available
11 / 17

Sequentially collected (longitudinal) surgical samples from the same donor

Approximate number of donors

20–70 sets per indication

Tumor types

NSCLC CRC Ovarian Head & Neck SCC Breast Gastric Endometrial RCC Bladder (UC) Melanoma

Follow-up data

Treatment Response OS/PFS

Mutations*

KRAS NRAS EGFR ALK fusion BRAF BRCA MET alteration HRD status MSI status

* as available from donor records

IHC markers

ER/PR HER2 MMR IHC PD-L1 TROP2 Nectin-4 B7-H3 B7-H4 DLL3 p16 p53

HBS formats

FFPE TMA Slides
Example HBS Cohorts & Data Available
12 / 17

Longitudinal Example: NSCLC.

Per-patient. Per matched metastasis. Treatment-line resolved. Examples below are anonymized records from the repository.

Patient #001 Immunotherapy: NoTreatment status: Treatment naïve
  1. Primary specimen Surgery: Left lung upper lobectomy and lymph node sampling Site: Lung, left upper lobe
  2. Matched met 1 Site: Superficial cerebrum and dura Treatment: Immunotherapy naïve
Patient #002 Immunotherapy: NoTreatment status: Treatment naïve
  1. Primary specimen Surgery: Left Thoracotomy and upper lobectomy with wedge of the lower lobe taken en bloc. Sleeve resection of PA Site: Left lung, upper lobe
  2. Matched met 1 Site: Lymph node Treatment: Treatment naïve
  3. Matched met 2 Site: Lymph node Surgery date: Q1-2018 Treatment: Treatment naïve
Patient #007 Immunotherapy: No
  1. Matched met 1 Site: Lymph node Treatment: Treatment naïve
  2. Matched met 2 Site: Lymph node Treatment: Treatment naïve
  3. Matched met 3 Site: Hilar Lymph node Surgery date: Q1-2022 Treatment: Treatment naive Block #: C7
Example HBS Cohorts & Data Available
13 / 17

Primary & matched distant metastases (surgical samples)

Approximate number of donors

20–50 sets per indication

Tumor types

NSCLC CRC Ovarian Head & Neck SCC Breast Gastric Endometrial Bladder (UC) Melanoma RCC

Examples of metastatic sites

Lymph nodes Bone Liver Lung Brain Peritoneal

*Mets only (without matched primary) samples available

Follow-up data

Treatment Response OS/PFS

Mutations*

KRAS NRAS EGFR ALK fusion BRAF BRCA MET alteration HRD status MSI status

*As available from donor records.

IHC markers

ER/PR HER2 MMR IHC PD-L1 TROP2 Nectin-4 B7-H3 B7-H4 DLL3 p16 p53

HBS formats

FFPE Slides TMA Block or slides
Example HBS Cohorts & Data Available
14 / 17

Pre & Post standard of care (SOC) treatment surgical samples

Includes a sub-set of donor matched sets.

Approximate number of donors

25–150 per indication

Tumor types

NSCLC CRC Ovarian Head & Neck SCC Breast Gastric Endometrial Pancreatic ADC Bladder (UC) Melanoma RCC

Follow-up data

Treatment Response OS/PFS

Mutations*

KRAS NRAS EGFR ALK fusion BRAF BRCA MET alteration HRD status MSI status

* as available from donor records

IHC markers

ER/PR HER2 MMR IHC PD-L1 TROP2 Nectin-4 B7-H3 B7-H4 DLL3 p16 p53

HBS formats

FFPE TMA Slides
Example HBS Cohorts & Data Available
15 / 17

Pre & Post IO (Pembro/Nivo) treatment surgical samples

1st line SOC chemo, 2nd line IO. Includes a sub-set of donor matched sets.

Approximate number of donors

10–25 per indication

Tumor types

NSCLC RCC Head & Neck SCC Melanoma

Follow-up data

Treatment Response OS/PFS

Mutations*

KRAS NRAS EGFR ALK fusion BRAF BRCA MET alteration HRD status MSI status

* as available from donor records

IHC markers

ER/PR HER2 MMR IHC PD-L1 TROP2 Nectin-4 B7-H3 B7-H4 DLL3 p16 p53

HBS formats

FFPE Slides TMA Block or slides
Example HBS Cohorts & Data Available
16 / 17

FFPE blocks & TMAs with matched double-spun plasma.

FFPE block & 4ml matched double-spun plasma or whole blood.

~330

Total sample sets

8

Indications

40 / 60

Stage I–II / III–IV (%)

5–20min

Ischemic time

Indication FFPE blocks Plasma / blood NGS-eligible†
NSCLC50●●
CRC100●●
Gastric ADC30●●
RCC30●●
Esophageal cancer40●●
Endometrial cancer50●●
Ovarian cancer20●●
Melanoma10●●

Compatible assays

IHC RNA-ISH NGS (Oncomine)

† NGS (Oncomine) panel can be ordered separately on any indication.

Note — these sets do not have outcome data and were collected from Ukraine.

Quantities are approximate and subject to change.

Example HBS Cohorts & Data Available